Patent expiries and challenges have done little to halt the sales of some of the industry's biggest products.
Using EvaluatePharma data Vantage explored investment trends in biopharma and medtech, sales per employee at big drug makers, and the declining number of late-stage…
The biotech financing scene in Europe continues to be dwarfed by the US, but on some measures the region is on an even footing.
A handful of tumour types have disproportionately benefited from the sector’s huge push into oncology. Is the investment case weakening in certain areas?
With only 18 novel drugs approved by the FDA so far this year, the influential US regulator looks set to dim the green lights in 2019.
The overall rate of device approvals in 2019 is holding steady on last year – but the types of approvals are different.
Up-front fees paid out by biopharma companies to seal licensing deals noticeably dipped in the second quarter of the year – then Gilead and Galapagos came along.